• Product nameAnti-TCF7L2 antibody [EP2033Y]
    See all TCF7L2 primary antibodies
  • Description
    Rabbit monoclonal [EP2033Y] to TCF7L2
  • Tested applicationsSuitable for: WB, IP, IHC-P, Flow Cyt, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide. within Human TCF7L2 aa 1-100 (N terminal). The exact sequence is proprietary.
    Database link: Q9NQB0

  • Positive control
    • Jurkat cell lysate; HeLa cells; human breast carcinoma tissue.
  • General notes

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.


    Alternative versions available:

    Anti-TCF7L2 antibody (Alexa Fluor® 488) [EP2033Y] (ab206062)
    Anti-TCF7L2 antibody (Alexa Fluor® 647) [EP2033Y] (ab206063)



Our Abpromise guarantee covers the use of ab76151 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/25000 - 1/100000. Predicted molecular weight: 68 kDa.
IP 1/50.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Flow Cyt 1/50. ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
ICC/IF 1/100 - 1/250.


  • FunctionParticipates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.
  • Tissue specificityDetected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.
  • Involvement in diseaseNote=Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).
    Genetic variations in TCF7L2 are associated with susceptibility to non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
  • Sequence similaritiesBelongs to the TCF/LEF family.
    Contains 1 HMG box DNA-binding domain.
  • Developmental stageHighly expressed in crypt regions and barely detectable in villi in epithelium from fetal small intestine at week 16. At week 22 expression in villi had increased strongly.
  • DomainThe promoter-specific activation domain interacts with the transcriptional coactivator EP300.
  • Post-translational
    In vitro, phosphorylated by TNIK.
    Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylated by AXAM/SENP2. Sumoylation/desumoylation regulates TCF4 transcription activity in the Wnt signaling pathway without altering interaction with CTNNB1 nor binding DNA.
  • Cellular localizationNucleus > PML body. Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.
  • Information by UniProt
  • Database links
  • Alternative names
    • HMG box transcription factor 4 antibody
    • hTCF 4 antibody
    • hTCF-4 antibody
    • T cell factor 4 antibody
    • T cell specific HMG box antibody
    • T cell specific transcription factor 4 antibody
    • T-cell factor 4 antibody
    • T-cell-specific transcription factor 4 antibody
    • TCF 4 antibody
    • TCF-4 antibody
    • TCF4 antibody
    • TCF7L2 antibody
    • TCF7L2 protein antibody
    • TF7L2_HUMAN antibody
    • Transcription factor 7 like 2 antibody
    • Transcription factor 7 like 2 T cell specific HMG box antibody
    • Transcription factor 7-like 2 antibody
    see all

Anti-TCF7L2 antibody [EP2033Y] images

  • Immunofluorescence staining of HT-29 cells with purified ab76151 at a working dilution of 1/250, counter-stained with DAPI. The secondary antibody was an Alexa Fluor® 488 conjugated goat anti-rabbit (ab150077), used at a dilution of 1/1000. The cells were fixed in 4% PFA and permeabilized using 0.1% Triton X 100. The negative control is shown in bottom right hand panel - for the negative control, PBS was used instead of the primary antibody.

  • Anti-TCF7L2 antibody [EP2033Y] (ab76151) at 1/2000 dilution + Mouse kidney

    Predicted band size : 68 kDa
  • Anti-TCF7L2 antibody [EP2033Y] (ab76151) at 1/100000 dilution + Jurkat cell lysate at 10 µg

    goat anti-rabbit HRP at 1/1000 dilution

    Predicted band size : 68 kDa
    Observed band size : 68 kDa
  • ab76151 at 1/100 dilution staining T cell Transcription Factor 4 in human breast carcinoma by Immunohistochemistry, Paraffin-embedded tissue.
  • Overlay histogram showing Jurkat cells stained with ab76151 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76151, 1/50 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

References for Anti-TCF7L2 antibody [EP2033Y] (ab76151)

This product has been referenced in:
  • Guo W  et al. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma. PLoS One 9:e85766 (2014). WB ; Human . Read more (PubMed: 24465691) »
  • Xu X  et al. Thymine DNA glycosylase is a positive regulator of Wnt signaling in colorectal cancer. J Biol Chem 289:8881-90 (2014). WB, IP ; Human . Read more (PubMed: 24532795) »

See all 5 Publications for this product

Product Wall

Thank you for contacting us and your interest in our products. I am pleased to provide the following immunogen information: xxxxxx of human T cell Transcription Factor 4 In order to aid your research we are happy to provide this information ...

Read More

Thank you for contacting Abcam.

The concentration of the antibody varies slightly from batch to batch, so if you could provide me with the lot number of the vial you have, I would be happy to find out the concentration for you.

I lo...

Read More